Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
复制标题
对标题为“伊立替康 UGT1A1 基因型指导给药：代谢不良患者的前瞻性安全性和成本分析：是否是每个接受伊立替康治疗的人都进行 UGT1A1 基因多态性检测的时候了”的信件的回应？
DOI：
10.1016/j.ejca.2022.05.045
复制
发表时间：
2022
影响因子：
8.4
通讯作者：
M. Deenen
中科院分区：
文献类型：
--
作者：
E. Hulshof;M. de With;G. Creemers;H. Guchelaar;R. Mathijssen;H. Gelderblom;M. Deenen
